Middle East IVD Market (2025-2032)
The Middle East IVD Market was valued at $1.57 billion in 2024. This market is expected to reach $2.15 billion by 2032, from an estimated $1.63 billion in 2025, at a CAGR of 4.1% during the forecast period 2025-2032. Middle East IVD Market Size & Forecast In vitro diagnostics (IVD) are tests performed
- Published
- Jan 2024
- Pages
- 200
- Format
- PDF + Excel
- Report ID
- MRHC - 1041081
- Base year
- 2024
- 2024 · BASELINE
- $1.57B
- 2032
- $2.15B
- CAGR 2025–2032
- 4.1%
2024 baseline · 2025–2032 forecast at 4.1% CAGR · hover a bar for the value
Key highlights
In 2025, the Kits & Reagents Segment is Expected to Dominate this Market
In 2025, the Molecular Diagnostics Segment is Expected to Account for the Largest Share of the Market
The Cardiology Segment Is Projected to Register the Highest CAGR During the Forecast Period
In 2025, the Laboratory Testing Segment is Expected to Dominate this Market
The Hospitals & Clinics Segment Is Projected to Register the Highest CAGR During the Forecast Period
Report summary
| Particulars | Details |
|---|---|
| Number of Pages | ~200 |
| Format | |
| Forecast Period | 2025-2032 |
| Base Year | 2024 |
| CAGR | 4.1% |
| Estimated Market Size (Value) | $2.15 billion by 2032 |
| Segments Covered | By Offering · Kits & Reagents · Instruments · Software & Services · By Technology · Molecular Diagnostics · Polymerase Chain Reaction (PCR) · Hybridization · Isothermal Nucleic Acid Amplification Technology · DNA Sequencing & Next-generation Sequencing · Microarrays · Mass Spectrometry · Other Molecular Diagnostic Technologies · (Note: Other Molecular Diagnostic Technologies majorly include electrophoresis, Ligase Chain Reaction (LCR), Northern Blot, and Southern Blot) · Point of Care (PoC) Diagnostics · Lateral Flow Assays/Rapid Tests · POC Molecular Diagnostics · Other PoC Products · (Note: Other PoC products include coagulation tests and blood glucose monitoring systems.) · Immunoassay/Immunochemistry · Enzyme-linked Immunosorbent Assays (ELISA) · Radioimmunoassays · Western Blotting · Enzyme-Linked Immunospot Assays · Immunohistochemistry (IHC) · Biochemistry/Clinical Chemistry · Metabolic Panel · Electrolyte Panel · Liver Panel · Lipid Profile · Renal Profile · Thyroid Function Panel · Whole Blood Glucose Monitoring · Microbiology · Hematology · Coagulation/Hemostasis · Urinalysis · Other IVD Technologies · (Note: Other IVD technologies comprise anatomical pathology, histochemistry, and loop-mediated amplification) · By Application · Infectious Diseases · COVID-19 Testing · Sexually Transmitted Diseases (STD) Testing · Healthcare-associated Infections (HAIs) · Hepatitis · HIV · Tropical Diseases · Respiratory Infections (Excluding Influenza) · Influenza · Other Infectious Diseases · (Note: Other infectious diseases include congenital infections, meningitis, norovirus (stomach flu), hand, foot, and mouth disease (HFMD), and pertussis.) · Oncology · Diabetes · Cardiology · Nephrology · Autoimmune Disorders · Other Applications · (Note:Other applications comprise drugs of abuse tests, coagulation tests, neonatal testing, genetic testing, and neurological disorders testing.) · By Diagnostic Approach · Lab Testing · OTC/Self-testing · Point of Care Testing · By End User · Diagnostic Laboratories · Hospitals & Clinics · Home Healthcare · Other End Users · (Note:Other end users comprise nursing homes, academic & research institutes, ambulatory care centers, and transfusion laboratories.) |
| Countries Covered | Saudi Arabia, UAE, Qatar, Kuwait, Oman, Israel, and the Rest of the Middle East |
| Key Companies | The key players operating in the Middle East IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), BioMérieux S.A. (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Illumina, Inc. (U.S.), QuidelOrtho Corporation. (U.S.), Agilent Technologies, Inc. (U.S.), and DiaSorin S.p.A. (Italy). |
Report overview
Segments covered: offering, technology, application, diagnostic approach.
In vitro diagnostics (IVD) are tests performed on biological samples such as blood, saliva, and other tissues taken from the human body to detect a wide range of diseases. IVD tests are used to screen biological samples to monitor individuals’ health and prevent or diagnose diseases. These consist of various tests based on techniques such as enzyme-linked immunosorbent assay (ELISA), radioimmunoassay, polymerase chain reaction (PCR), isothermal nucleic acid amplification, and next-generation sequencing. These tests can be performed in laboratories, homes, and healthcare facilities.
The growth of the Middle East IVD market is attributed to the rising prevalence of chronic and infectious diseases, the growing demand for point-of-care (PoC) and rapid diagnostics, rising healthcare expenditures, growth in the aging population, and rising awareness about healthcare. However, high prices for IVD tests and the variance in test results observed in rapid IVD tests restrain the growth of the IVD market.
The rising awareness regarding early disease diagnosis and increasing inclination toward personalized medicine in the UAE and Saudi Arabia are expected to create growth opportunities for the players operating in this market. However, the concerns pertaining to false positive results in immunoassays and POC are a major challenge for market growth.
Report infographic
Market dynamics
2 factors across 2 forcesRising Prevalence of Chronic Diseases is Driving the Growth of this Market
Chronic diseases are often associated with the elderly population due to the declining bodily functions and immunity among this population segment. Aging is associated with progressive deterioration in the structure and functioning of organs. The elderly population is more prone to various chronic diseases. According to the World Bank, in 2022, in Iran, Saudi Arabia, and the UAE, the percentage of the elderly population out of the total population was 8%, 3%, and 2% respectively.
The prevalence of chronic diseases and conditions such as cancer, diabetes, arthritis, and heart disease are on the rise in Middle East countries. According to GLOBOCAN, in Israel, the prevalence of cancer is expected to increase to 44.2 thousand cases in 2040 from 28.7 thousand cases in 2020. Similarly, in Saudi Arabia, the prevalence of cancer is expected to increase to 60.4 thousand cases in 2040 from 27.9 thousand cases in 2020. Early detection is very important in reducing mortality in the case of cancer, improving the chances of survival, and saving on treatment costs. Various rapid diagnostic kits are used to detect cancer. The demand for IVD kits for cancer testing is expected to grow significantly in the coming years.
The growth in the geriatric population and social behaviors such as tobacco and alcohol consumption, physical inactivity, and unhealthy diets are major factors driving a steady increase in the number of people suffering from chronic diseases. The growth in the elderly population and the associated increase in the burden of chronic disease is increasing the demand for IVD testing in the Middle East.
Table of contents
13 chapters · 130 sections · 200 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Offering | Kits & Reagents | — |
| By Technology | Molecular Diagnostics | — |
| By Application | — | Cardiology |
| By Diagnostic Approach | Laboratory Testing | — |
| By End User | — | Hospitals & clinics |
By Offering
- The kits & reagents segment is expected to account for the largest share of the market.
- The large market share of this segment is attributed to the frequent use of reagents and kits in the detection of various chronic diseases, the commercial availability of a diverse range of reagents and consumables for the diagnosis of various diseases, ease of use of reagents & kits, and emerging threat of infectious diseases.
- For instance, according to WHO, between 2012 and October 2022, 2,600 laboratory-confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection have been identified, of which 84% (2,193/2,600) have been reported in Saudi Arabia.
- Thus, the emerging threat of infectious diseases is increasing the demand for kits & reagents for rapid testing.
By Technology
- The molecular diagnostics segment is expected to account for the largest share of the market.
- The growing prevalence of infectious diseases, technological innovations, and the advantages of molecular diagnostics tests, such as cost-effectiveness, rapid results, and high sensitivity and specificity over laboratory tests
- Additionally, the strategic initiatives adopted by key players in the region are expected to support the largest share of the segment.
- In June 2021, G42 Healthcare (UAE) signed a Memorandum of Understanding (MoU) with Seegene Inc. (South Korea) to offer fully equipped mobile diagnostics and testing laboratories across the Middle East and North Africa (MENA) region.
- The partnership was aimed at providing the Seegene Mobile Station, a laboratory-on-wheels facility to provide optimized molecular diagnosis and tests across MENA, including the UAE, Algeria, Morocco, Tunisia, Libya, Egypt, Sudan, Palestine, Jordan, Syria, Iraq, Iran, Pakistan, Lebanon, Kuwait, Qatar, Oman, Saudi Arabia, Bahrain, and Yemen.
By Application
- The Cardiology Segment Is Projected to Register the Highest CAGR During the Forecast Period
- The cardiology segment is expected to register the highest CAGR during the forecast period.
- Cardiovascular diseases (CVD) remain the leading cause of death globally.
- IVD testing is used for biomarker detection in cardiology.
- The early-stage biomarkers of CVD can potentially save many lives and help alleviate the global burden of CVD.
- The increasing prevalence of cardiovascular diseases, the growing global geriatric population, and increasing research on cardiac biomarkers are expected to drive the growth of this segment.
By Diagnostic Approach
- The laboratory testing segment is expected to account for the largest share of the market.
- The large market share of this segment is primarily attributed to its higher accuracy and reliability, lower costs, and availability of several IVD tests in laboratory settings.
- Additionally, the laboratory testing landscape is changing in Middle East countries; due to emerging threats of epidemics, governments, along with interest groups are working to increase the rate of laboratory testing in the region.
- For instance, in February 2024, GC Labs (South Korea) is planning to expand its network of diagnostic laboratories in the UAE and increase access to lab testing in the country.
By End User
- The hospitals & clinics segment is expected to register the highest CAGR during the forecast period.
- The highest CAGR of this segment is attributed to the increasing number of hospitalizations due to various diseases requiring diagnosis and the rise in the number of hospitals and clinics in the region, leading to growth in the utilization of diagnostic products.
- For instance, as of 2022, in UAE, the number of private medical facilities reached 4,482, including 56 hospitals and 55,208 licensed medical professionals (Source: Dubai Healthcare City Authority).
Geographic analysis
Middle East & Africa
Fastest growthSaudi Arabia is expected to register the highest CAGR during the forecast period. The highest CAGR of this regional market is attributed to the rising healthcare expenditure, the growing aging population, and the increasing adoption of self-testing. Additionally, the rising chronic and infectious diseases are increasing the demand for IVD. Chronic diseases such as ischemic heart disease, stroke, chronic obstructive pulmonary disease (COPD), and cancer are responsible for most deaths in Saudi Arabia. For example, in 2021, 4.3 million people aged 20–79 years were living with diabetes in Saudi Arabia. This number grew with a CAGR of 3.4% (from 2011–2021) from 2.8 million in 2011 (Source: IDF Diabetes Atlas 2021). Thus, the demand for IVD glucose testing is increasing in the country. The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over the years. The key players operating in the Middle East IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), BioMérieux S.A. (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Illumina, Inc. (U.S.), QuidelOrtho Corporation. (U.S.), Agilent Technologies, Inc. (U.S.), and DiaSorin S.p.A. (Italy). Saudi Arabia: Fastest Growing Market Middle East IVD Market: Key Players
Competitive landscape
- Abbott Laboratories (U.S.)
- Becton
- Dickinson and Company (U.S.)
- BioMérieux S.A. · France
- Danaher Corporation (U.S.)
- F. Hoffmann-La Roche · Switzerland
- QIAGEN N.V. · Netherlands
- Siemens Healthineers AG · Germany
- Thermo Fisher Scientific Inc. (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- Illumina, Inc. (U.S.)
- QuidelOrtho Corporation. (U.S.)
- Agilent Technologies, Inc. (U.S.)
- DiaSorin S.p.A · Italy
Frequently asked questions
The Middle East IVD market is segmented based on product & solution (reagents & kits, systems, and software & services) and a wide range of technologies (immunoassay/immunochemistry, biochemistry/clinical chemistry, molecular diagnostics, microbiology, hematology, coagulation/hemostasis, urinalysis, and other technologies) offered by key companies to various end users, such as diagnostic laboratories, hospitals & clinics, home healthcare, and other end users. The Middle East IVD market studied in this report involves the value analysis of various segments and sub-segments of in-vitro diagnostics at regional and country levels.
Cite this report
Meticulous Research. (2024). Middle East IVD Market - Opportunity Analysis and Industry Forecast (2025-2032) (Report No. MRHC - 1041081). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/middle-east-ivd-market-5764